Biomea Fusion (BMEA) AI Stock Analysis

• Market Cap: $114.54M
• Dividend Yield: N/A
• Average Volume (3M): 2.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: N/A
• EPS Growth: 40.22%
• Country: US
• Employees: 79
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 70,703,636
• 10 Day Avg. Volume: 5,869,688
• 30 Day Avg. Volume: 2,395,415
• PEG Ratio: -0.09
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.16
• Enterprise Value/Market Cap: 0.21
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -47.93
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $7.80
• Price Target Upside: 381.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.50 ▼(-7.41% Downside)

The score is primarily held back by weak financial performance (no revenue, large losses, and significant cash burn with a shrinking equity base). Offsetting this are improving technical momentum and a supportive, positive pipeline update from the recent JPM conference event, while valuation remains difficult to assess due to ongoing losses and no dividend.

Positive Factors

Leadership Change

The appointment of a new interim CEO can bring fresh strategic direction, potentially enhancing the company's focus on advancing its treatment pipeline.

Drug Discovery Platform

Biomea's proprietary platform targeting genetic mutations in cancer cells represents a strong competitive advantage in developing innovative treatments.

Low Debt Levels

Low debt levels provide Biomea with financial flexibility and reduce risk, allowing focus on R&D and strategic initiatives without heavy debt burdens.

Negative Factors

Revenue Generation Challenges

The lack of revenue generation is a significant concern, impacting profitability and the ability to sustain operations without external funding.

Negative Cash Flows

Persistent negative cash flows indicate potential liquidity issues, limiting Biomea's ability to invest in growth and development without additional capital.

Declining Equity

Declining equity suggests weakening financial stability, potentially affecting investor confidence and the ability to secure future funding.

Biomea Fusion Business Overview & Revenue Model

Company Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

How the Company Makes Money

Biomea Fusion makes money through the development and eventual commercialization of its proprietary small molecule drug candidates. The company invests in research and development to advance its drugs through clinical trials. Revenue generation is primarily expected to occur upon successful commercialization of these drugs, either directly or through partnerships and licensing agreements with larger pharmaceutical companies. Additionally, Biomea may engage in strategic collaborations to co-develop treatments, which can provide milestone payments and royalties contingent upon the success of the drug candidates.

Biomea Fusion Financial Statement Overview

Summary

Biomea Fusion is facing significant challenges in financial performance, primarily due to its inability to generate revenue. The company's financial health is concerning, with increasing net losses and negative cash flows. The balance sheet offers some relief with low debt levels, but declining equity and negative operating cash flows pose substantial risks. The company needs to focus on revenue generation and cash flow management to improve its financial standing.

Income Statement

Biomea Fusion has struggled with consistent revenue generation, as evidenced by zero revenue across the years. The company's net losses have increased significantly, with the most recent annual report showing a net income of -$138 million. The absence of revenue highlights a critical challenge for the company, affecting profitability margins such as gross profit, EBIT, and EBITDA, all of which are negative.

Balance Sheet

The balance sheet indicates a relatively low debt-to-equity ratio, thanks to a modest amount of total debt compared to equity. However, the significant decline in equity from $169 million in 2023 to $51 million in 2024 raises concerns. High cash reserves compared to total debt suggest good liquidity, yet with shrinking equity, the financial stability is weakening.

Cash Flow

Operating cash flows have been deeply negative, with no signs of improvement. The free cash flow remains negative, but the drop in operating cash flow in 2024 to zero indicates a potential cash crunch. The inability to generate positive cash flow from operations is a key risk for the company's financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-500.00K	0.00	0.00	0.00	0.00	-132.00K
EBITDA	-95.07M	-142.32M	-124.62M	-82.94M	-41.42M	-5.19M
Net Income	-95.71M	-138.43M	-117.25M	-81.83M	-41.57M	-5.32M
Balance Sheet
Total Assets	55.19M	79.94M	199.93M	129.31M	185.71M	62.53M
Cash, Cash Equivalents and Short-Term Investments	46.64M	58.28M	176.87M	113.05M	173.52M	61.70M
Total Debt	6.88M	8.77M	10.30M	2.29M	2.85M	259.00K
Total Liabilities	39.57M	28.36M	30.69M	20.77M	6.92M	57.36M
Stockholders Equity	15.62M	51.57M	169.24M	108.54M	178.78M	5.17M
Cash Flow
Free Cash Flow	-87.14M	-120.26M	-99.96M	-63.45M	-38.61M	-4.51M
Operating Cash Flow	-87.06M	-119.89M	-96.59M	-62.42M	-35.44M	-4.46M
Investing Cash Flow	-82.00K	-362.00K	-2.22M	27.34M	-33.35M	-51.00K
Financing Cash Flow	45.83M	1.67M	163.80M	1.24M	153.19M	65.97M

Biomea Fusion Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.62
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Neutral. The current price of 1.62 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.28, and below the 200-day MA of 1.70, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 52.50 is Neutral, neither overbought nor oversold. The STOCH value of 74.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMEA.

Biomea Fusion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$107.11M	-1.40	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OVID	51 Neutral	$117.50M	-3.11	-60.06%	―	946.61%	-11.30%
BMEA	50 Neutral	$114.54M	-0.58	-209.00%	―	―	40.22%
INO	46 Neutral	$112.67M	-0.61	-328.45%	―	-10.36%	42.36%
ATOS	45 Neutral	$77.76M	-2.47	-48.89%	―	―	-9.42%
AGEN	41 Neutral	$159.16M	-1.73	―	―	-33.41%	81.19%

Biomea Fusion Corporate Events

Biomea Fusion Highlights Diabetes Pipeline at JPM Conference

On January 14, 2026, Biomea Fusion presented updated data on its diabetes and obesity pipeline at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and concurrently refreshed its corporate presentation for ongoing use with investors and analysts. The company highlighted clinical and preclinical results for its lead candidate icovamenib, showing that a 12-week dosing regimen in severe insulin-deficient type 2 diabetes patients produced durable reductions in HbA1c and increased insulin secretion measured by C-peptide index up to nine months after treatment ended, alongside evidence of enhanced beta-cell mass and function and improved GLP-1 receptor and insulin transcript levels in human islets, with a generally favorable safety profile and low rates of serious adverse events, underscoring its bid to differentiate in a crowded diabetes market by targeting disease progression rather than symptoms.

The most recent analyst rating on (BMEA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Biomea Fusion stock, see the BMEA Stock Forecast page.